Background: Androgen deprivation therapy has long been the mainstay of treatment for advanced prostate cancer, but tumors inevitably become castration-resistant prostate cancer (CRPC). Increasing evidence suggests that persistent androgen receptor (AR) signaling plays an essential role in development of hormone therapy resistance. It has been shown recently that enhancer RNAs (eRNAs) is widely transcribed from cell lineage-specific enhancers. Mechanistic studies show that in a locus-specific manner, eRNAs act in cis to stabilize enhancer-promoter looping, establish chromatin accessibility or facilitate release of the negative elongation factor (NELF) complex. Estrogen receptor (ER)-or ARregulated eRNAs also act in trans to regulate gene expression in hormone-responsive cells, but the effects appear to be relatively infrequent in the cell types examined. To date, however, the function and disease relevance of AR-bound enhancer RNAs (AR-eRNAs) remain poorly understood.
